SCHEMBL4067192

SCHEMBL4067192

COC(=Nc1cc(-c2ccccc2)n[nH]1)C(CC(=O)O)NC(=O)C(O)c1cc(F)cc(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39
GAA P10253 1/20 0.38
ACR P10323 2/20 0.37
MME P08473 1/20 0.36
CASP1 P29466 2/20 0.35
CASP3 P42574 2/20 0.35
CASP7 P55210 2/20 0.35
CASP8 Q14790 2/20 0.35
MAPK8 P45983 1/20 0.35
CTSA P10619 4/20 0.35
CHEK1 O14757 1/20 0.34
RET P07949 1/20 0.34
PDGFRB P09619 1/20 0.34
PIM1 P11309 1/20 0.34
PDGFRA P16234 1/20 0.34
GSK3B P49841 1/20 0.34
RPS6KA3 P51812 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4058459 0.90 CASP1 (0.36) ADORA3ADORA2AADORA2BADORA1MME
SCHEMBL4064462 0.76 ADORA3 (0.40) ADORA3ADORA2AADORA2BADORA1GAA
SCHEMBL4056317 0.74 PSEN1 (0.44) ADORA3ADORA2AADORA2BADORA1GAA
SCHEMBL4062416 0.71 PSEN1 (0.46) ADORA3ADORA2AADORA2BADORA1GAA
SCHEMBL4056892 0.70 PSEN1 (0.41) ADORA3ADORA2AADORA2BADORA1ACR
SCHEMBL4058454 0.70 MMP9 (0.42) ADORA3ADORA2AADORA2BADORA1ACR
SCHEMBL4055360 0.65 MAPK8 (0.39) ADORA3ADORA2AADORA2BADORA1MME
SCHEMBL4058155 0.64 ADORA3 (0.45) ADORA3ADORA2AADORA2BADORA1GAA
SCHEMBL2821840 0.61 PSEN1 (0.56) MMEPSEN1PSEN2APH1BNCSTN
SCHEMBL3903388 0.61 PSEN1 (0.56) MMEPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070270474-A1 drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome PFIZER INC. 2007-11-22 US claimed
US-7238721-B2 Pyrazole compounds for treatment of neurodegenerative disorders PFIZER INC (US) 2007-07-03 US claimed
US-20040142997-A1 Pyrazole compounds for treatment of neurodegenerative disorders PFIZER INC. 2004-07-22 US claimed
US-7521464-B2 Pyrazole compounds for treatment of neurodegenerative disorders PFIZER INC. (US) 2009-04-21 US disclosed
US-20070270474-A1 drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome PFIZER INC. 2007-11-22 US disclosed
US-7238721-B2 Pyrazole compounds for treatment of neurodegenerative disorders PFIZER INC (US) 2007-07-03 US disclosed
US-20040142997-A1 Pyrazole compounds for treatment of neurodegenerative disorders PFIZER INC. 2004-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142997-A1 Pyrazole compounds for treatment of neurodegenerative disorders APP, PARK7, BACE1 ADORA3 30/4885ADORA2A 357/4885ADORA2B 379/4885
US-20070270474-A1 drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome APP, BACE1, PSEN1 ADORA3 97/4885ADORA2A 214/4885ADORA2B 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.